The conventional classification of acute myocardial infarction (AMI) into ST-segment elevation (STEMI) and non-ST-segment elevation (NSTEMI) has long guided clinical decision-making. However, emerging ...
Medical Management/Treatment Initial treatment for suspected STEMI and NSTEMI requires a loading dose of nonenteric coated ASA at 162 to 325 mg (unless contraindicated), nitroglycerin in response to ...
Incidence patterns of ST-elevation myocardial infarction and non-ST-elevation myocardial infarction in type 1 diabetes are influenced by age, vascular history, and kidney function. ST-elevation ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
In patients with first-time non-ST-segment elevation myocardial infarction (non-STEMI), a combination of reduced left ventricular ejection fraction (LVEF) and more extensive obstructive coronary ...
An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction that has been treated with guideline-recommended complete ...
In frail, elderly patients with non-ST-segment elevation myocardial infarction (NSTEMI), invasive management with coronary ...
The evidence supporting beta-blocker therapy after myocardial infarction was established before the introduction of modern coronary reperfusion therapy and secondary prevention strategies. In an ...
The excess risk persisted after discharge, suggesting the need for closer follow-up and intensified secondary prevention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results